control group:recombinant human erythropoietin

2 trials

Sponsors

The First Affiliated Hospital of Chengdu Medical College, Beijing Hepingli Hospital

Conditions

Hemodialysis combined with anemiacardio-renal-anemia syndrome

Early Phase 1

A practical randomized controlled trial of hypoxia inducible factor prolyl hydroxylase inhibitor in the treatment of cardio-renal-anemia syndrome

Active, not recruitingChiCTR2100050031

Beijing Hepingli Hospitalcardio-renal-anemia syndrome

Start: 2021-08-10Updated: 2022-04-19

Phase 4

Efficacy and safety of rosastatin capsules in hemodialysis patients with erythropoietin resistance

RecruitingChiCTR1900026596

The First Affiliated Hospital of Chengdu Medical CollegeHemodialysis combined with anemia

Start: 2019-10-22Updated: 2019-10-21

Related Papers

Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial

Frontiers in Medicine2022-04-045 citations